Oral ferrous fumarate dosing regimens in peritoneal dialysis: a single-center retrospective audit
Frontiers in Nephrology · 03.11.2026 · 6
DOI: 10.3389/fneph.2026.1989068 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Nephrology, online erschienen am 03.11.2026. Verfasst von Annie M Tijs und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology, Department of Internal Medicine, University of Groningen, University Medical Center Groningen, Groningen, Netherlands. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Anemia is highly prevalent in patients with kidney failure receiving peritoneal dialysis (PD). Oral iron supplementation is frequently prescribed, but adherence may be limited by pill burden and gastrointestinal adverse effects. Emerging evidence suggests that less frequent oral iron dosing may enhance iron absorption by reducing hepcidin-mediated inhibition, yet data in PD patients are lacking. We evaluated iron utilization and compared the effectiveness of different oral iron regimens in PD patients.
Methods
This retrospective cohort study (2007-2025) included adults (≥18 years) receiving peritoneal dialysis at the Dialysis Center Groningen who were treated with oral ferrous fumarate for ≥3 months. Patients receiving intravenous iron, other iron formulations, non-standard dosing regimens, or with active gastrointestinal bleeding were excluded. Ferrous fumarate regimens included 200 mg once daily (OD), twice daily (BID), three times daily (TID), or three times weekly (TIW). Patients not receiving oral iron were evaluated for treatment eligibility. Primary outcomes were 6-month changes in hemoglobin, ferritin, and transferrin saturation. Regimen-specific trajectories were analyzed using linear mixed-effects models. Sensitivity analyses adjusted for age, sex, erythropoiesis-stimulating agent dose, and inflammation, and were restricted to incident iron users on PD.
Results
Of the 140 patients screened, 85 patients were included (median age 61 years; 57.6% male). TIW dosing resulted in hemoglobin trajectories comparable to OD dosing (P = 0.30), with similar ferritin and transferrin saturation trajectories. In contrast, BID dosing was associated with a steeper hemoglobin increase (0.013 g/dL/day; P = 0.001) than OD dosing. Sensitivity analyses yielded similar results. Among patients not receiving iron therapy, 30% (n= 9/30) met contemporaneous guideline criteria for treatment.
Conclusion
In this 18-year retrospective study of 85 PD patients, TIW and OD oral iron supplementation produced comparable hematologic outcomes, suggesting that less frequent dosing may represent an effective strategy to reduce treatment burden without compromising efficacy. Twice-daily dosing was associated with faster hemoglobin increases, likely reflecting greater cumulative iron exposure. Iron therapy was underutilized in a substantial proportion of eligible patients. Although limited by the modest sample size, these findings highlight the need for expert consensus to address evidence gaps and guide anemia management in PD.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Nephrology, Department of Internal Medicine, University of Groningen, University Medical Center Groningen, Groningen, Netherlands.
- Dialysis Center Groningen, Groningen, Netherlands.
- Department of Nephrology and Hypertension, University Medical Center Utrecht, Utrecht, Netherlands.
- Department of Epidemiology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands.
Zitieren
APA
Tijs, A. M., Rawee, P., Yang, Y., Manson, N. A., Hazenberg, I. T., Westerhuis, R., Abrahams, A. C., Nolte, I. M., & Eisenga, M. F. (2026). Oral ferrous fumarate dosing regimens in peritoneal dialysis: a single-center retrospective audit. Frontiers in Nephrology, 6. https://doi.org/10.3389/fneph.2026.1989068
Vancouver
Tijs AM, Rawee P, Yang Y, Manson NA, Hazenberg IT, Westerhuis R, et al. Oral ferrous fumarate dosing regimens in peritoneal dialysis: a single-center retrospective audit. Frontiers in Nephrology. 2026;6. doi:10.3389/fneph.2026.1989068
BibTeX
@article{Tijs2026,
author = {Tijs, Annie M and Rawee, Pien and Yang, Yaqin and Manson, Nienke A and Hazenberg, Ietje T and Westerhuis, Ralf and Abrahams, Alferso C and Nolte, Ilja M and Eisenga, Michele F},
title = {Oral ferrous fumarate dosing regimens in peritoneal dialysis: a single-center retrospective audit},
journal = {Frontiers in Nephrology},
year = {2026},
volume = {6},
doi = {10.3389/fneph.2026.1989068}
}
EUVIMED